Recent Advances in Targeting ROS1 in Lung Cancer.

Recent Advances in Targeting ROS1 in Lung Cancer.
复制标题

DOI:
10.1016/j.jtho.2017.08.002
复制
发表时间:
2017-11
期刊:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子:
--
通讯作者:
Shaw AT
Shaw AT
中科院分区:
其他
文献类型:
--
作者:
Lin JJ;Shaw AT

文献摘要

参考文献

被引文献

相似文献

ROS 1是非小细胞肺癌(NSCLC)的有效治疗靶点。在一项I期研究中,多靶向MET/ALK/ROS 1抑制剂克唑替尼在ROS 1重排的NSCLC中表现出显著的疗效,因此于2016年获得美国食品药品监督管理局和欧洲药品管理局的批准。然而,与其他癌基因驱动的肺癌相似,用克唑替尼治疗的ROS 1重排肺癌最终获得耐药性,导致疾病复发。因此,需要新的ROS 1抑制剂和治疗策略。对ROS 1定向酪氨酸激酶抑制剂(TKI)耐药机制的深入了解现在开始出现,并有助于指导新的ROS 1抑制剂的开发。本文综述了ROS 1重排的非小细胞肺癌的生物学和诊断,以及目前和新兴的治疗方案。强调了该领域未来的挑战。
ROS1 is a validated therapeutic target in non-small cell lung cancer (NSCLC). In a phase I study, the multi-targeted MET/ALK/ROS1 inhibitor crizotinib demonstrated remarkable efficacy in ROS1-rearranged NSCLCs, and consequently gained approval by the United States Food and Drug Administration as well as the European Medicines Agency in 2016. However, similar to other oncogene-driven lung cancers, ROS1-rearranged lung cancers treated with crizotinib eventually acquire resistance, leading to disease relapse. Novel ROS1 inhibitors and therapeutic strategies are therefore needed. Insights into the mechanisms of resistance to ROS1-directed tyrosine kinase inhibitors (TKIs) are now beginning to emerge and are helping to guide the development of new ROS1 inhibitors. This review discusses the biology and diagnosis of ROS1-rearranged NSCLC, and current and emerging treatment options for this disease. Future challenges in the field are highlighted.
DOI: 10.1158/1078-0432.ccr-12-0550
发表时间: 2012-09-01
期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子: --
作者:
Davies KD;Le AT;Theodoro MF;Skokan MC;Aisner DL;Berge EM;Terracciano LM;Cappuzzo F;Incarbone M;Roncalli M;Alloisio M;Santoro A;Camidge DR;Varella-Garcia M;Doebele RC
通讯作者: Doebele RC
DOI: 10.1158/1541-7786.mcr-13-0479-t
发表时间: 2014-01
期刊: Molecular cancer research : MCR
影响因子: --
作者:
Aisner DL;Nguyen TT;Paskulin DD;Le AT;Haney J;Schulte N;Chionh F;Hardingham J;Mariadason J;Tebbutt N;Doebele RC;Weickhardt AJ;Varella-Garcia M
通讯作者: Varella-Garcia M
DOI: 10.1371/journal.pone.0028250
发表时间: 2011
期刊: PloS one
影响因子: 3.7
作者:
Birch AH;Arcand SL;Oros KK;Rahimi K;Watters AK;Provencher D;Greenwood CM;Mes-Masson AM;Tonin PN
通讯作者: Tonin PN
DOI: 10.1158/0008-5472.can-06-1193
发表时间: 2006-08-01
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Charest, Al;Wilker, Erik W.;Housman, David
通讯作者: Housman, David
DOI: 10.1016/j.jtho.2017.07.005
发表时间: 2017-09-01
影响因子: 20.4
作者:
Cho, Byoung Chul;Kim, Dong-Wan;Wrona, Anna
通讯作者: Wrona, Anna